Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 1/20 | 0.44 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30550842 | 0.86 | ALDH1A1 (0.41) | BCL6NCOR2SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL25323507 | 0.86 | ALDH1A1 (0.41) | BCL6NCOR2SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL1442559 | 0.82 | PGK1 (0.51) | BCL6SMN1; SMN2ALDH1A1KDM4ESTK17A | |
| SCHEMBL1937307 | 0.80 | ESR1 (0.49) | BCL6NCOR2ESR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1442231 | 0.79 | TRPM8 (0.54) | BCL6SMN1; SMN2ALDH1A1KDM4EHTT | |
| SCHEMBL26627874 | 0.78 | ALDH1A1 (0.41) | SMN1; SMN2ALDH1A1KDM4ESTK17AHTT | |
| SCHEMBL30462013 | 0.78 | ALDH1A1 (0.41) | SMN1; SMN2ALDH1A1KDM4ESTK17AHTT | |
| SCHEMBL25902572 | 0.78 | HTT (0.58) | BCL6SMN1; SMN2ALDH1A1KDM4ESTK17A | |
| SCHEMBL4144113 | 0.78 | ESR1 (0.46) | BCL6NCOR2ESR1ALDH1A1STK17A | |
| SCHEMBL13195718 | 0.77 | STK17A (0.49) | SMN1; SMN2ALDH1A1KDM4ESTK17AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2473486-B2 | PYRIMIDINES AS HEPCIDINE ANTAGONISTS | VIFOR INT AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| US-20200115343-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2020-04-16 | — | — | US | disclosed |
| US-20200115343-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2020-04-16 | — | — | US | disclosed |
| US-10577329-B2 | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-10577329-B2 | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190202790-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2019-07-04 | — | — | US | disclosed |
| US-20190202790-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2019-07-04 | — | — | US | disclosed |
| US-10294206-B2 | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | FORMA TM2, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-10294206-B2 | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | FORMA TM2, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20180141910-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | US | disclosed |
| US-9624175-B2 | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| WO-2016171755-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-10-27 | — | — | WO | disclosed |
| WO-2016171755-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-10-27 | — | — | WO | disclosed |
| US-20160311774-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-10-27 | — | — | US | disclosed |
| US-20160311774-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-10-27 | — | — | US | disclosed |
| US-20160311774-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-10-27 | — | — | US | disclosed |
| EP-2473486-B1 | PYRIMIDINES AS HEPCIDINE ANTAGONISTS | VIFOR INT AG (CH) | 2015-10-28 | — | — | EP | disclosed |
| US-20120202806-A1 | Novel Pyrimidine- And Triazine-Hepcidine Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-09 | — | — | US | disclosed |
| EP-2473486-A1 | NOVEL PYRIMIDINE AND TRIAZINE HEPCIDINE ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2012-07-11 | — | — | EP | disclosed |
| WO-2011026835-A1 | NOVEL PYRIMIDINE AND TRIAZINE HEPCIDINE ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311774-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH1, IDH3A, IDH3B | BCL6 497/4885NCOR2 292/4885ESR1 4019/4885 |
| US-20190202790-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH1, IDH3A, IDH3B | BCL6 497/4885NCOR2 292/4885ESR1 4019/4885 |
| US-20120202806-A1 | Novel Pyrimidine- And Triazine-Hepcidine Antagonists | HAMP, DHPS, SLC40A1 | BCL6 2208/4885NCOR2 857/4885ESR1 3166/4885 |
| US-10577329-B2 | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | IDH1, IDH3A, IDH3B | BCL6 497/4885NCOR2 292/4885ESR1 4019/4885 |
| US-20180141910-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH1, IDH3A, IDH3B | BCL6 467/4885NCOR2 295/4885ESR1 4008/4885 |
| US-10294206-B2 | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | IDH1, IDH3A, IDH3B | BCL6 467/4885NCOR2 295/4885ESR1 4008/4885 |
| US-20200115343-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH1, IDH3A, IDH3B | BCL6 497/4885NCOR2 292/4885ESR1 4019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.